Why did 190A.T stock fall so sharply today?

190A.T stock fell due to heavy selling that pushed volume to **6412000.00** shares, a relVolume of **7.93**, and a break below the 200-day average. Market reaction likely reflects valuation worries and absence of immediate positive clinical catalysts.

What does Meyka AI forecast for 190A.T stock?

Meyka AI's forecast model projects a monthly price of **126.08** JPY versus the current **130.00** JPY, implying an implied downside of **-3.08%**. Forecasts are model-based projections and not guarantees.

Is 190A.T stock a buy, hold, or sell now?

Meyka AI rates 190A.T **65.55/100** (Grade **B**) with a suggestion to **HOLD** based on sector, metrics, and growth factors. Investors should weigh clinical risk and liquidity before changing positions.

What key levels should traders watch for 190A.T stock?

Key technical levels are intraday low **128.00** JPY, 50-day average **117.26** JPY, and a year low at **98.00** JPY. Resistance is near **154.44** JPY, the 200-day average.

JP Stocks

Chordia (190A.T JPX) down 22.16% 03 Mar 2026: 190A.T stock shows short-term downside

ByDanny Kontos March 3, 2026March 3, 2026

Chordia Therapeutics (190A.T) plunged 22.16% to JPY 130.00 at the JPX close on 03 Mar 2026, marking one of the top losers on the session. The drop followed a surge in intraday volume to 6412000.00 shares versus an average of 1738356.00, signalling heavy sell pressure. This move pushed the share price below the 200-day average of 154.44 JPY and raised fresh questions about valuation and near-term catalysts for the 190A.T stock.